Galaxy Biotech LLC jumped back into the big fish pond, inking exclusive worldwide development and commercialization rights to a humanized monoclonal antibody (mAb) targeting fibroblast growth factor 2 (FGF2) in cancer to Roche AG. Read More
A federal court has turned down the Patent and Trademark Office's (PTO) request that judges look again at January's ruling on the statutory deadline for legal challenges to patent term adjustments. Read More
While studying premature ovarian aging, a team of scientists has discovered an unexpected connection between BRCA1/2 and FMR1 – genes that are both famous for reasons other than their effects on fertility. Read More
Launch of the nonprofit TransCelerate BioPharma Inc. by 10 of the industry's largest pharmas was greeted with interest and a bit of skepticism last week at the BioPharm America 2012 conference in Boston. Read More
• EpiCept Corp., of Tarrytown, N.Y., said it reduced the exercise price of certain of its outstanding common stock purchase warrants in return for their immediate cash exercise. Read More
• Bioceros BV, of Utrecht, the Netherlands, a participant in the ACCESS project consortium led by Synthon BV, of Nijmegen, the Netherlands, received a GO EFRO grant to develop improved antibody manufacturing systems. Other partners in the consortium include IBIS Technologies BV, Infors Benelux BV and Wageningen University. Read More
• Seattle Genetics Inc., of Bothell, Wash., and Millennium: The Takeda Oncology Co., of Cambridge, Mass., completed patient enrollment in a Phase III trial of Adcetris (brentuximab vedotin) in post-transplant Hodgkin lymphoma (HL). Read More
